Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Noonan syndrome 8 News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A recent study evaluates the molecular genetics and clinical manifestations of patients with LZTR1-associated Noonan syndrome. This retrospective chart review contributes to the understanding of the genetic underpinnings and clinical features of this rare condition.

Research shows that rigosertib effectively reverses hypertrophic cardiomyopathy in patients with Noonan syndrome. This finding could lead to new therapeutic strategies for managing this rare condition.

FDA expands the approval of Sogroya for once-weekly treatment in children with idiopathic short stature (ISS), small for gestational age (SGA), and Noonan syndrome. This new authorization enhances treatment options for pediatric patients with these conditions.

Not rare diseases news,news about your rare disease.

Earlier

A recent study evaluates the molecular genetics and clinical manifestations of patients with LZTR1-associated Noonan syndrome. This retrospective chart review contributes to the understanding of the genetic underpinnings and clinical features of this rare condition.

Research shows that rigosertib effectively reverses hypertrophic cardiomyopathy in patients with Noonan syndrome. This finding could lead to new therapeutic strategies for managing this rare condition.

FDA expands the approval of Sogroya for once-weekly treatment in children with idiopathic short stature (ISS), small for gestational age (SGA), and Noonan syndrome. This new authorization enhances treatment options for pediatric patients with these conditions.

Not rare diseases news,
news about your rare disease.